Cancer Immunology Immunotherapy, Год журнала: 2022, Номер 71(12), С. 2999 - 3011
Опубликована: Май 22, 2022
Язык: Английский
Cell Reports Medicine, Год журнала: 2022, Номер 3(11), С. 100785 - 100785
Опубликована: Окт. 19, 2022
To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), chemotherapy (gemcitabine and cisplatin), combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) explore predictors, we perform a multi-center, real-world cohort study that enrolls 253 treated treatments (combination therapy: 98, chemotherapy: 107, immunotherapy: 48) from 15 tertiary hospitals. We demonstrate achieves highest complete response rate pathological downstaging compared or chemotherapy. develop validate an prediction model consisting pretreatment clinical characteristics, which can pinpoint candidates to receive therapy. also preliminarily reveal who achieve after plus maximal transurethral resection tumor may be safe preservation Overall, this highlights benefit based on tislelizumab for MIBC.
Язык: Английский
Процитировано
68
Cancers, Год журнала: 2022, Номер 14(13), С. 3181 - 3181
Опубликована: Июнь 29, 2022
Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence progression rate. In recent years, immense amounts studies have been carried out to bring a more comprehensive cognition numerous promising clinic approaches BCa therapy. The development innovative enhanced cystoscopy techniques (optical techniques, imaging systems) tumor biomarkers-based non-invasive urine screening (DNA methylation-based test) would dramatically improve accuracy detection, reducing risk BCa. Moreover, intravesical instillation systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine targeted therapy) also provide plentiful measures break predicament Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, bladder preservation emerged continually, which are supposed be candidates treatment. Here, advances prospects diagnosis, or treatment, drug delivery systems therapy reviewed in this paper.
Язык: Английский
Процитировано
41
Cell & Bioscience, Год журнала: 2023, Номер 13(1)
Опубликована: Окт. 13, 2023
Immunotherapy is one of the fastest developing areas in field oncology. Many immunological treatment strategies for refractory tumors have been approved and marketed. Nevertheless, much clinical preclinical experimental evidence has shown that efficacy immunotherapy tumor varies markedly among individuals. The commensal microbiome mainly colonizes intestinal lumen humans, affected by a variety factors exhibits individual variation. Moreover, gut considered largest immune organ body due to its influence on system. In last few decades, with development next-generation sequencing (NGS) techniques in-depth research, view microbiota intervenes antitumor through system gradually confirmed. Here, we review important studies published recent years focusing influences progression malignancy. Furthermore, discuss mechanism which affect immunotherapy, including checkpoint blockade (ICB) adoptive T-cell therapy (ACT), modulating microbial composition facilitate response. Finally, opportunity some challenges are mentioned enable more systematic understanding future promote basic research application related fields.
Язык: Английский
Процитировано
23
Protein & Cell, Год журнала: 2024, Номер 15(6), С. 419 - 440
Опубликована: Фев. 29, 2024
Tumor-resident microbiota in breast cancer promotes initiation and malignant progression. However, targeting to improve the effects of therapy has not been investigated detail. Here, we evaluated composition tumors found that enterotoxigenic Bacteroides fragilis (ETBF) was highly enriched patients who did respond taxane-based neoadjuvant chemotherapy. ETBF, albeit at low biomass, secreted toxic protein BFT-1 promote cell stemness chemoresistance. Mechanistic studies showed directly bound NOD1 stabilized protein. expressed on ALDH+ stem cells (BCSCs) cooperated with GAK phosphorylate NUMB its lysosomal degradation, thereby activating NOTCH1-HEY1 signaling pathway increase BCSCs. inhibition ETBF clearance chemosensitivity by impairing
Язык: Английский
Процитировано
13
Trends in cancer, Год журнала: 2024, Номер 10(4), С. 347 - 355
Опубликована: Фев. 22, 2024
Tumor-resident microbes (TRM) are an integral component of the tumor microenvironment (TME). TRM can influence growth, distant dissemination, and response to therapies by interfering with molecular pathways in cells as well other components TME. Novel technologies improving identification visualization cell type-specific The mechanisms that mediate role at primary tumors metastatic sites being elucidated. This knowledge is providing novel perspectives for targeting or using microbial interventions cancer interception therapy.
Язык: Английский
Процитировано
9
Communications Biology, Год журнала: 2021, Номер 4(1)
Опубликована: Авг. 26, 2021
Abstract Mechanomedicine is an emerging field focused on characterizing mechanical changes in cells and tissues coupled with a specific disease. Understanding the cues that drive disease progression, whether tissue stiffening can precede development, crucial order to define new biomarkers improve develop diagnostic prognostic tools. Classically known stromal regulators, such as fibroblasts, more recently acknowledged factors microbiome extracellular vesicles, play role modifications stroma matrix (ECM). These ultimately lead alteration of properties (stiffness) tissue, contributing onset progression. We describe here classic mediators ECM remodeling, discuss state-of-the-art studies fingerprints urological diseases, showing general trend between increased stiffness severity Finally, we point clinical potential factor field, well possible target for innovative drugs.
Язык: Английский
Процитировано
50
Seminars in Cancer Biology, Год журнала: 2022, Номер 86, С. 875 - 884
Опубликована: Янв. 1, 2022
Язык: Английский
Процитировано
31
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Фев. 22, 2023
Gut microbiota represents a hidden treasure vault encompassing trillions of microorganisms that inhabit the intestinal epithelial barrier host. In past decade, numerous in-vitro , animal and clinical studies have revealed profound roles gut in maintaining homeostasis various physiological functions, especially immune modulation, remarkable differences configuration microbial communities between cancers healthy individuals. addition, although considerable efforts been devoted to cancer treatments, there remain many patients succumb their disease with incremental burden worldwide. Nevertheless, compared stability human genome, plasticity renders it promising opportunity for individualized treatment. Meanwhile, burgeoning findings indicate is involved close interactions outcomes diverse immunotherapy protocols, including checkpoint blockade therapy, allogeneic hematopoietic stem cell transplantation, chimeric antigen receptor T therapy. Here, we reviewed evidence capacity microflora modulate immunotherapies, highlighted opportunities microbiota-based prognostic prediction, as well microbiotherapy by targeting potentiate anticancer efficacy while attenuating toxicity, which will be pivotal development personalized treatment strategies.
Язык: Английский
Процитировано
19
European Urology, Год журнала: 2024, Номер 85(5), С. 417 - 421
Опубликована: Янв. 5, 2024
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that microbiome is central player immune-mediated anticancer activity. This report aimed investigate composition and role of stool enrolled trial. An orthotopic animal model (MB49-Luc) was used support some findings from human data. analysis before conducted 42 patients, whom 23 showed pathologic response. The information preclinical treated with anti–PD-1 antibody or control isotype validated. Linear discriminant effect size linear models were identify bacterial taxa enriched either responders nonresponders. identified also tested their association event-free survival (EFS). Survival at 31 d after tumor instillation study endpoint model. Responders nonresponders emerged differ terms enrichment 16 taxa. Of these, genus Sutterella responders, while species Ruminococcus bromii negative impact R. on activity observed EFS bromii. We found different associated response lack neoadjuvant pembrolizumab. Moreover, we provided experimental about Further studies are needed externally validate our provide mechanistic insights host-pathogen interactions MIBC. Using prepembrolizumab samples collected trials, who responded did not respond immunotherapy. an cancer, gathered further evidence efficacy. confirm current test utility these bacteria predictive markers
Язык: Английский
Процитировано
7
Cancer Science, Год журнала: 2024, Номер 115(8), С. 2578 - 2587
Опубликована: Апрель 29, 2024
Bacterial flora are present in various parts of the human body, including intestine, and thought to be involved etiology diseases such as multiple sclerosis, intestinal diseases, cancer, uterine diseases. In recent years, presence bacterial 16S rRNA genes has been revealed blood, which was previously a sterile environment, characteristic blood microbiomes have detected However, mechanism origin information unknown. this study, we performed metagenomic analysis DNA serum extracellular vesicles from five healthy donors seven patients with renal cell carcinoma Cutibacterium acnes carcinoma. addition, C. significantly reduced postoperative compared that preoperative these also tumor tissue tissue-associated microbiota, suggesting an association between were taken up by cells enhance their proliferative potential. exhibited tumor-promoting activity mouse model cancer allografts enhanced angiogenesis. These results suggest released localized tissues act manner.
Язык: Английский
Процитировано
7